[go: up one dir, main page]

DK1578446T3 - Anti-cd33-antistoffer og fremgangsmåde til behandling af akut myeloid leukæmi ved anvendelse heraf - Google Patents

Anti-cd33-antistoffer og fremgangsmåde til behandling af akut myeloid leukæmi ved anvendelse heraf Download PDF

Info

Publication number
DK1578446T3
DK1578446T3 DK03779105.0T DK03779105T DK1578446T3 DK 1578446 T3 DK1578446 T3 DK 1578446T3 DK 03779105 T DK03779105 T DK 03779105T DK 1578446 T3 DK1578446 T3 DK 1578446T3
Authority
DK
Denmark
Prior art keywords
ser
antibody
amino acid
acid sequence
gly
Prior art date
Application number
DK03779105.0T
Other languages
English (en)
Inventor
Mary G Hoffee
Daniel Tavares
Robert J Lutz
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Application granted granted Critical
Publication of DK1578446T3 publication Critical patent/DK1578446T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

  1. ANTI-CD33-ANTISTOFFER OG FREMGANGSMÅDE TIL BEHANDLING AF AKUT MYELOID LEUKÆMI VED ANVENDELSE HERAF
    1. CD33-specifikt antistof omfattende: (i) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGK ATLT ADKS STT A YMQLS SLTSEDS AV Y YC ARE VRLR YFDV WGQGTTVTV SS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSOKNYLAWYQQIPGQSPRLLIYW ASTRES GVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKR; (ii) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGK ATLT ADKS STT A YMOLS SLTSEDS AV YYC ARE VRLR YFDV WGQGTTVIVS S; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIMLIQSPGSLAVSPGERVTMSCKSSQSVFFSSSOKNYLAWYQQIPGQSPKWYW ASTRES OVPDRFTGSOSOTDFTT TTSS VOPEDT ,ΑΤΥΥΓΗΟΥΤ .S S R TFGOGTKT .F.TKR; (iii) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: OVOLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGKATLT ADKSSTT AYMQLS SLTSEDS AV YYC AREVRLRYFDVWGQGTTVTVSS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYVV ASTRE S GVPDRFTGS GSGTDFTLTIS S VQPEDL AI YYCHQ YLS SRTFGQGTKLEIKR; (iv) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGKATLT ADKSSTT AYMQLSSLTSEDS AVYYCARE VRLR YFDVWGQGTTVTVSS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIMLTQSPGSLAVSPGERVIMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYWASTRES G VPDRFTGSGS GTDFTLTIS S VQPEDLAIYY CHQYLS S RTFGQGTKLEIKR; (v) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGKATLTADKSSTTAYMQLSSLTSEDSAVYYCAREVRLR YFDVWGQGTTVTVSS; Og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIMLTQSPGSLAVSPGERVIMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYW ASTRES G VPDRFTGSGS GTDFTLTIS S VQPEDLAIYYCHQYLS S RTFGQGTKLEIKR; (vi) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGK ATLT ADKS STTAYMQLS SLTSEDS AV YY C ARE VRLRYFDV WGQGTTVTV SS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: ErVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPKLLIYW ASTRES GVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKR; (vii) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGK ATLT ADKS STT A YMQLS SLTSEDS AV YY C ARE VRLRYFDV WGQGTTVTV SS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPKLLIYW ASTRES GVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKR; (viii) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYI HWIKQTPGQGLEWVGVIYPGNDDISYNQKFQGKATLTADKSSTTAYMQLSSLTSEDSAVY YC ARE VRLR YFD VWGQGTT VT VS S; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIMLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYW ASTRES G VPDRFTGSGS GTDFTLTIS S VQPEDLAI YY CHQYLS S RTFGQGTKLEIKR; (ix) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGKATLT ADKS STT AYMQLSSLTSEDS AV YY C ARE VRLRYFDVWGQGTTVTVSS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIMLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYW ASTRES G VPDRFTGSGS GTDFTLTIS S VQPEDLAI YY CHQYLS S RTFGQGTKLEIKR; (x) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGK ATLT ADKS STTAYMQLS SLTSEDS AV YYC ARE VRLRYFDV VVGQGTT VI VS S °g en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIMLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPKLLIYW ASTRES G VPDRFTGSGS GTDFTLTIS S VQPEDLAIYYCHQYLS S RTFGQGTKLEIKR; (xi) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGK ATLT ADKS STT A YMQLSSLTSEDS AV YY C ARE VRLRYFDVWGQGTTVTV SS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIMLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPKLLIYW ASTRES GVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKR; (xii) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGK ATLT ADKS STT A YMQLS SLTSEDS AV YY C ARE VRLRYFDV WGQGTTVTV SS; °g en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYW ASTRES GVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKR; (xiii) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGKATLTADKSSTTAYMQLSSLTSEDSAVYYCAREVRLRYFDVWGQGTTVTVSS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYW ASTRES GVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKR; (xiv) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGKATLTADKS STT AYMQLSSLTSEDS A V Y Y C ARE VRLRYFDVWGQGTTVTV SS; °g en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQI PGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGT KLEIKR; eller (xv) en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFKGKATLT ADKS STTAYMQLS SLTSEDS AV YY C ARE VRLRYFDVWGQGTTVTV SS; og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: NIVLTQSPGSLAVSPGERVIMSCKSSQSVFFSSSQKNYLAWYQQ1PGQSPKLLIWASTRESG VPDRFTGS GS GTDFTLTIS S VQPEDLAIYYCHQYLS SRTFGQGTKLEIKR.
  2. 2. CD33-specifikt antistof ifølge krav 1, hvilket antistof omfatter en variabel tungkæderegion omfattende en aminosyresekvens repræsenteret ved: QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDIS YNQKFQGKATLT ADKS STTAYMQLS SLTSEDS AV YYC ARE VRLRYFDVWGQGTTVTVSS (SEQ ID NO: 9), og en variabel letkæderegion omfattende en aminosyresekvens repræsenteret ved: EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQ IPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGT KLEIKR (SEQ ID NO: 10).
  3. 3. Immunkonjugat, der omfatter antistoffet ifølge krav 1 eller 2, er bundet til et lægemiddel eller en prodrug.
  4. 4. Immunkonjugat ifølge krav 3, hvor lægemidlet eller prodrug’en er udvalgt fra gruppen bestående af et maytansinoid, et taxoid, CC-1065, en CC-1065-analog, dolastatin, en dolastatinanalog, methotrexat, daunorubicin, doxorubicin, vineristin, vinblastin, melphalan, mitomycin C, chlorambucil, calicheamicin og derivater deraf.
  5. 5. Sammensætning omfattende antistoffet ifølge krav 1 eller 2 og et lægemiddel eller en prodmg.
  6. 6. Farmaceutisk sammensætning omfattende antistoffet ifølge krav 1 eller 2, eller immunkonjugat eller sammensætning ifølge krav 3 til 5 og et farmaceutisk acceptabelt middel.
  7. 7. Fremgangsmåde in vitro til hæmning af væksten af en celle, der udtrykker CD33, hvilken fremgangsmåde omfatter etablering af kontakt mellem cellen og antistoffet ifølge krav 1 eller 2, immunkonjugatet ifølge krav 3 eller 4, sammensætningen ifølge krav 5 eller en farmaceutisk sammensætning ifølge krav 6.
  8. 8. Antistof ifølge krav 1 eller 2, immunkonjugat ifølge krav 3 eller 4, sammensætning ifølge krav 5 eller farmaceutisk sammensætning ifølge krav 6 til anvendelse som et medikament.
  9. 9. Anvendelse af antistoffet ifølge krav 1 eller 2, immunkonjugatet ifølge krav 3 eller 4, sammensætningen ifølge krav 5 eller den farmaceutiske sammensætning ifølge krav 6 i fremstillingen af et medikament til behandling af cancer.
  10. 10. Antistof ifølge krav 1 eller 2, immunkonjugat ifølge krav 3 eller 4, sammensætning ifølge krav 5 eller farmaceutisk sammensætning ifølge krav 6, til anvendelse i behandling af cancer.
  11. 11. Anvendelse eller antistof, immunkonugat, sammensætning eller farmaceutisk sammensætning til anvendelse ifølge krav 9 eller 10, hvor canceren er udvalgt fra gruppen bestående af akut myeloid leukæmi (AML), kronisk myeloid leukæmi (CML) og pro-myelocytisk leukæmi (PML).
  12. 12. Isoleret polynukleotid, der koder for antistoffet ifølge krav 1 eller 2.
  13. 13. Isoleret polynukleotid, der koder for en let og en tung kæde af antistoffet ifølge krav 1 eller 2.
  14. 14. Rekombinant vektor omfattende polynukleotidet ifølge krav 12 eller 13.
  15. 15. Værtscelle transformeret med den rekombinante vektor ifølge krav 14.
  16. 16. Fremgangsmåde til frembringelse af et CD33-specifikt antistof, hvilken fremgangsmåde omfatter (a) dyrkning af en værtscelle ifølge krav 15 på betingelser, således at værtscellen udtrykker antistoffet, og (b) indsamling af det således udtrykte antistof.
DK03779105.0T 2002-11-07 2003-11-05 Anti-cd33-antistoffer og fremgangsmåde til behandling af akut myeloid leukæmi ved anvendelse heraf DK1578446T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42433202P 2002-11-07 2002-11-07
PCT/US2003/032737 WO2004043344A2 (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same

Publications (1)

Publication Number Publication Date
DK1578446T3 true DK1578446T3 (da) 2015-06-29

Family

ID=32312793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03779105.0T DK1578446T3 (da) 2002-11-07 2003-11-05 Anti-cd33-antistoffer og fremgangsmåde til behandling af akut myeloid leukæmi ved anvendelse heraf

Country Status (25)

Country Link
US (10) US7557189B2 (da)
EP (1) EP1578446B1 (da)
JP (1) JP5354835B2 (da)
KR (1) KR20050059332A (da)
CN (2) CN1795009B (da)
AU (1) AU2003285878B2 (da)
BR (1) BR0316101A (da)
CA (1) CA2504818C (da)
CO (1) CO5580797A2 (da)
CR (1) CR7853A (da)
CY (1) CY1116406T1 (da)
DK (1) DK1578446T3 (da)
EA (1) EA010570B1 (da)
EC (1) ECSP055831A (da)
ES (1) ES2539627T3 (da)
HK (1) HK1091132A1 (da)
HU (1) HUE026914T2 (da)
IL (2) IL168295A (da)
MX (1) MXPA05004712A (da)
NO (1) NO338498B1 (da)
NZ (1) NZ539395A (da)
PT (1) PT1578446E (da)
SI (1) SI1578446T1 (da)
WO (1) WO2004043344A2 (da)
ZA (1) ZA200503075B (da)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795009B (zh) * 2002-11-07 2014-07-09 伊谬诺金公司 抗-cd33抗体及其用途
EP1799259B1 (en) 2004-10-12 2012-12-05 Crucell Holland B.V. Binding molecules for the detection of cancer
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
NZ716641A (en) 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
HUE039385T2 (hu) 2007-04-12 2018-12-28 Brigham & Womens Hospital Inc ABCB5 rákterápiás célzása
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR101764081B1 (ko) 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 가교제 및 그 용도
EA030182B1 (ru) 2009-04-20 2018-07-31 Оксфорд Байотерепьютикс Лтд. Антитела, специфические для кадгерина-17
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
RU2646139C1 (ru) 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
US8524240B2 (en) 2009-10-26 2013-09-03 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
BR112012022338A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais direcionados a cd20
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
CN103534268B (zh) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 抗体
WO2012074097A1 (ja) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 抗ｃｄ３３抗体
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
SG195172A1 (en) 2011-06-21 2013-12-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
KR102080535B1 (ko) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Her3에 특이적인 결합 분자 및 이의 용도
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN102768283B (zh) * 2012-07-23 2015-03-04 北京大学人民医院 一种检测或辅助检测髓系白血病细胞分化阶段的试剂盒
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
CA2883222C (en) 2012-08-31 2021-12-14 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AU2014285079A1 (en) 2013-07-05 2016-01-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble CD33 for treating myelodysplastic syndromes (MDS)
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3461845B1 (en) 2013-12-13 2020-09-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
CA2928952A1 (en) * 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016014072B1 (pt) * 2013-12-17 2023-12-26 Kling Biotherapeutics B.V. Anticorpo isolado, sintético ou recombinante humano, ou uma parte funciona do mesmo, molécula de ácido nucleico isolado, vetor, composição, uso de um anticorpo ou parte funcional, ou uma molécula de ácido nucleico ou um vetor e, métodos para produzir um anticorpo ou parte funcional, e para determinar se céuluas aml ou células de linfoma ou células de mieloma múltiplo ou células b de linfoma não hodgkin estão presentes em uma amostra
DK3126390T3 (da) 2014-04-03 2020-01-20 Cellectis Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
CN111560071B (zh) 2014-04-08 2023-09-05 波士顿制药有限公司 对il-21具有特异性的结合分子及其用途
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
CA2947602A1 (en) * 2014-05-20 2015-11-26 Immunogen, Inc. Methods for characterizing and treating acute myeloid leukemia
EP3172234B1 (en) * 2014-07-21 2020-04-08 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG11201701328XA (en) 2014-09-02 2017-03-30 Immunogen Inc Methods for formulating antibody drug conjugate compositions
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
HUE051002T2 (hu) 2014-09-03 2021-01-28 Immunogen Inc Citotoxikus benzodiazepin származékok
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
KR102207381B1 (ko) * 2014-10-23 2021-01-27 싱 몰레큘러 메디신, 엘엘씨 세포내 항원에 대해 지향된 단일 도메인 항체
SG11201703332SA (en) 2014-11-10 2017-05-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
WO2016075176A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR102597989B1 (ko) * 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
JP6688551B2 (ja) 2015-05-21 2020-04-28 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
CA2987037A1 (en) 2015-05-29 2016-12-08 Amphivena Therapeutics, Inc. Use of cd33/cd3 bispecific tandem diabodies for the treatment of acute myeloid leukemia (aml)
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2016201388A2 (en) * 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
US10898579B2 (en) 2015-06-29 2021-01-26 Immunogen, Inc. Conjugates of cysteine engineered antibodies
PL3313884T3 (pl) 2015-06-29 2021-05-31 Immunogen, Inc. Przeciwciała anty-cd123 oraz ich koniugaty i pochodne
TWI726936B (zh) 2015-11-10 2021-05-11 美商麥迪紐有限責任公司 對asct2具專一性之結合分子及其用途
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
KR20180105233A (ko) 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법
WO2017156488A2 (en) 2016-03-10 2017-09-14 Acceleron Pharma, Inc. Activin type 2 receptor binding proteins and uses thereof
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
CN116217731A (zh) 2016-04-22 2023-06-06 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017274442B2 (en) 2016-06-02 2021-08-19 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
PE20191319A1 (es) * 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
JP2020500214A (ja) 2016-11-02 2020-01-09 イミュノジェン・インコーポレーテッド 抗体薬物複合体とｐａｒｐ阻害剤との併用治療
TWI845890B (zh) 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
PE20200012A1 (es) 2016-11-23 2020-01-06 Bioverativ Therapeutics Inc Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド 抗ｃｄ３３イムノコンジュゲート投与計画
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
IL273384B2 (en) 2017-09-22 2023-12-01 Immunogen Inc Methods of preventing methionine oxidation in immunoconjugates
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
JP2021508714A (ja) 2017-12-28 2021-03-11 イミュノジェン・インコーポレーテッド ベンゾジアゼピン誘導体
KR20200135331A (ko) 2018-02-14 2020-12-02 비엘라 바이오, 인크. 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
US11555070B2 (en) * 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
JP7386800B2 (ja) 2018-03-14 2023-11-27 メモリアル スローン－ケタリング キャンサー センター 抗ポリシアル酸抗体およびその使用
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
CA3100386A1 (en) * 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
BR112021003843A2 (pt) * 2018-08-28 2021-05-25 Ambrx, Inc. biconjugados de folato de anticorpo anti-cd3 e seus usos
PE20211096A1 (es) 2018-08-31 2021-06-14 Alector Llc Anticuerpos anti-cd33 y metodos para usarlos
WO2020056170A1 (en) * 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
US12103969B2 (en) * 2018-09-25 2024-10-01 Academia Sinica Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof
WO2020077258A1 (en) * 2018-10-12 2020-04-16 Jeanmarie Guenot Cd33×cd3 binding proteins for treating inflammatory conditions and diseases
CA3118816A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
SG11202109569RA (en) 2019-03-21 2021-10-28 Immunogen Inc Methods of preparing cell-binding agent-drug conjugates
TW202102506A (zh) 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
RS64961B1 (sr) 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
CN114007642A (zh) 2019-04-30 2022-02-01 森迪生物科学公司 嵌合受体及其使用方法
JOP20210289A1 (ar) 2019-05-20 2023-01-30 Servier Lab مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP3990022A4 (en) * 2019-06-26 2023-06-28 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN116670268A (zh) 2019-11-22 2023-08-29 免疫医疗有限公司 包含e2泛素或泛素样缀合结构域和用于特异性蛋白质降解的靶向结构域的融合蛋白
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116194476A (zh) * 2020-04-14 2023-05-30 维尔生物科技有限公司 针对sars-cov-2的抗体和其使用方法
EP4178611A1 (en) 2020-07-07 2023-05-17 BioNTech SE Therapeutic rna for hpv-positive cancer
MX2023002940A (es) 2020-09-11 2023-04-11 Medimmune Ltd Moleculas de union a b7-h4 terapeuticas.
JP2023542301A (ja) 2020-09-12 2023-10-06 メディミューン リミテッド 抗ｂ７ｈ４抗体薬物コンジュゲート療法のためのスコア化方法
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
KR20230143605A (ko) 2020-11-24 2023-10-12 노파르티스 아게 Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN117062611A (zh) 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
JP7574467B2 (ja) 2021-03-18 2024-10-28 メドイミューン・リミテッド 治療用結合分子
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
WO2024249925A1 (en) * 2023-06-01 2024-12-05 Research Institute At Nationwide Children's Hospital Cd-33 protein-binding compositions and methods related thereto
WO2025027472A2 (en) 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPH05503632A (ja) 1989-12-14 1993-06-17 スローン　―　ケターリング・インスティチュート・フォー・キャンサー・リサーチ モノクローナル抗体ｍ１９５の超可変領域の治療的使用およびその構築
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
CA2418014C (en) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia
JP4171816B2 (ja) * 2001-01-26 2008-10-29 インヒビテックス インコーポレーテッド Ｃｌｆａタンパク質に対するモノクローナル抗体および感染症を処置または予防することにおける使用の方法
CN1795009B (zh) * 2002-11-07 2014-07-09 伊谬诺金公司 抗-cd33抗体及其用途
EA200702239A1 (ru) * 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
KR20110028450A (ko) * 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
CA2947602A1 (en) * 2014-05-20 2015-11-26 Immunogen, Inc. Methods for characterizing and treating acute myeloid leukemia

Also Published As

Publication number Publication date
EP1578446A4 (en) 2008-07-30
US10000566B2 (en) 2018-06-19
HUE026914T2 (en) 2016-08-29
IL168295A (en) 2011-02-28
KR20050059332A (ko) 2005-06-17
AU2003285878A1 (en) 2004-06-03
CR7853A (es) 2005-12-16
HK1091132A1 (en) 2007-01-12
US20060177455A1 (en) 2006-08-10
US8337855B2 (en) 2012-12-25
NZ539395A (en) 2009-01-31
EA010570B1 (ru) 2008-10-30
NO20052693L (no) 2005-06-06
PT1578446E (pt) 2015-07-22
US20110008840A1 (en) 2011-01-13
CY1116406T1 (el) 2017-02-08
WO2004043344A3 (en) 2004-12-09
AU2003285878B2 (en) 2011-04-28
US20160362490A1 (en) 2016-12-15
US7557189B2 (en) 2009-07-07
ZA200503075B (en) 2006-09-27
JP5354835B2 (ja) 2013-11-27
CN1795009A (zh) 2006-06-28
CA2504818A1 (en) 2004-05-27
NO338498B1 (no) 2016-08-22
CA2504818C (en) 2013-04-23
US20130078241A1 (en) 2013-03-28
CN102875680B (zh) 2015-04-22
CN102875680A (zh) 2013-01-16
IL211385A0 (en) 2011-04-28
BR0316101A (pt) 2005-09-27
US20140248267A1 (en) 2014-09-04
SI1578446T1 (sl) 2015-07-31
NO20052693D0 (no) 2005-06-06
ES2539627T3 (es) 2015-07-02
US20110206700A1 (en) 2011-08-25
US20090291090A1 (en) 2009-11-26
WO2004043344A2 (en) 2004-05-27
CN1795009B (zh) 2014-07-09
US8119787B2 (en) 2012-02-21
US20050118183A1 (en) 2005-06-02
US20080167458A1 (en) 2008-07-10
US8747851B2 (en) 2014-06-10
CO5580797A2 (es) 2005-11-30
JP2006505277A (ja) 2006-02-16
EA200500778A1 (ru) 2006-02-24
ECSP055831A (es) 2005-08-11
EP1578446B1 (en) 2015-04-08
EP1578446A2 (en) 2005-09-28
US20180362646A1 (en) 2018-12-20
MXPA05004712A (es) 2005-11-23
US7342110B2 (en) 2008-03-11
US9359442B2 (en) 2016-06-07

Similar Documents

Publication Publication Date Title
DK1578446T3 (da) Anti-cd33-antistoffer og fremgangsmåde til behandling af akut myeloid leukæmi ved anvendelse heraf
US20210128742A1 (en) CD123 Antibodies and Conjugates Thereof
AU2014342610A1 (en) Anti-EFNA4 antibody-drug conjugates